ArticleDrug delivery and translational research2026
Solid microneedle booster as an enhanced microneedling platform for the treatment of androgenetic alopecia.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Solid microneedle (SMN) is used to enhance transfollicular delivery in androgenetic alopecia (AGA); however, user-dependent kinematics can generate irregular microchannels that require sequential drug application. Here, we developed a one-step solid microneedle booster (SMB) that combines spring-driven perpendicular stamping with simultaneous liquid dosing. This circumvents the spatial and temporal mismatch inherent in traditional two-step methods, improving microchannel reproducibility and early transport. In porcine skin, rhodamine B mapping exhibited higher microchannel surface coverage for SMB than that of the roller at 20 matched applications, with SMB producing deeper penetration. Functional delivery was evaluated by Franz diffusion using ascorbic acid as a hydrophilic probe of microchannel-assisted permeation. Across the various tested conditions, SMB consistently produced a stronger early-phase permeation enhancement than that of the roller, and this early advantage was reflected in the cumulative delivery at later time points. SMB-assisted minoxidil (MXD) delivery accelerated hair regrowth in vivo compared with roller-assisted delivery under matched treatment settings, and histological analysis supported these outcomes as it revealed a greater enrichment of deep follicles in the SMB + MXD groups. Collectively, SMB provides a directionality-controlled, one-step microneedling platform that enhances the early, front-loaded transport and promotes follicular maturation, with AGA serving as a representative model for the broader applications of dermatologic delivery.
Indexed as
Identifiers
42228320What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.